The Wrap: Viagem medicinal

1 min read
01_Blog_1440x956_(5).png

Possivelmente a droga mais antiga do mundo, cogumelos alucinógenos estão prestes a chegar ao mainstream. Não, eles não estão se tornando drogas lícitas como o álcool e tabaco (ainda), mas o governo federal dos EUA concedeu financiamento a pesquisadores para estudar os benefícios da psilocibina, o principal ingrediente psicoativo dos cogumelos.

Mais especificamente, uma doação de US$ 4 milhões do National Institutes of Health (NIH) para pesquisa pretende avaliar o impacto dos cogumelos em ajudar as pessoas a parar de fumar. Mas isso também é o que os cigarros eletrônicos afirmam resolver, então que outros benefícios existem, além de uma potencial bad trip?

Bem, aparentemente os benefícios são muitos. Os psicodélicos supostamente ajudam a tratar a depressão e até mesmo a controlar o vício em álcool. E apesar de o governo dos EUA ter parado de financiar pesquisas com psicodélicos na década de 1970, mais pesquisas continuam a surgir, pois o setor privado aparentemente não recebeu o memorando. A Data Bridge Market Research estima que o mercado global de psilocibina farmacêutica chegará a US$ 6,9 bilhões até 2027.

Aqui estão dois exemplos de estudos atuais: o St Vincent’s Hospital em Sydney está testando o uso de psilocibina para parar ou reduzir o uso de metanfetamina. E a Compass Pathways (CMPS) tem o COMP360, uma terapia com psilocibina que está sendo testada para uso em depressão resistente a outras formas de tratamento, transtorno de estresse pós-traumático e transtorno depressivo agudo.

Os cogumelos estão invadindo o mainstream cultural ultimamente, com Harry Styles alegando que eles aumentaram sua criatividade e Joe Rogan usando as substâncias durante a gravação um podcast de 3,5 horas com Post Malone. Agora é a comunidade científica que está aderindo à crescente crença de que os cogumelos podem ser apenas uma das próximas grandes drogas milagrosas.


Subscribe

By subscribing, you agree to our Privacy Policy.

Footer


Made in Australia

Sydney, Australia


Get the app

Scan QR code to download the app

Stakeshop Pty Ltd, trading as Stake, ACN 610 105 505, is an authorised representative (Authorised Representative No. 1241398) of Stakeshop AFSL Pty Ltd (Australian Financial Services Licence no. 548196). Stake SMSF Pty Ltd ACN 648 283 532 (‘Stake Super’) is not licensed to provide financial product advice under the Corporations Act. This specifically applies to any financial products which are established if you instruct Stake Super to set up a self managed super fund (‘SMSF’). When you sign up to Stake Super, you are contracting with Stake SMSF Pty Ltd who will assist in the establishment of a SMSF under a ‘no advice model’. You will also be referred to Stakeshop Pty Ltd to enable your trading account and bank account to be set up in order to use the Stake Website and/or App. For more information about SMSFs, see our SMSF Risks page. The Stake Accumulate Fund (ARSN 680 653 374) is issued by K2 Asset Management Ltd (ABN 95 085 445 094 AFSL 244 393), a wholly owned subsidiary of K2 Asset Management Holdings Ltd (ABN 59 124 636 782). The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake and Stake Super, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice given by Stake is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Financial Services Guide, Terms & Conditions, Privacy Policy and Disclaimers before deciding to invest on or use Stake or Stake Super. By using our website or service in any way, you agree to our Privacy Policy and Terms & Conditions. All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake and Stake Super are registered trademarks in Australia.

This information is being provided in connection with the Australian retail offer component of the initial public offering of shares of Class A common stock (“Shares”) in Anthropic, PBC (“Anthropic”) (“IPO”). The Australian retail offer is an offer of newly issued Shares by Anthropic (“Australian Retail Offer”) made under the Australian prospectus lodged with the Australian Securities and Investments Commission on 11 November 2026 (“Australian Prospectus”). This information does not form part of the Australian Prospectus, and anyone considering applying for Shares under the Australian Retail Offer should rely only on information in the Australian Prospectus and any supplementary or replacement Australian Prospectus. A copy of the Australian Prospectus is available on ipo.anthropic.com. Further information about Anthropic, the IPO, the Shares and the risks of investing in Anthropic is set out in the Australian Prospectus. Anyone considering applying for Shares under the Australian Retail Offer should read and consider the Australian Prospectus in full in deciding whether to acquire Shares under the Australian Retail Offer. Anyone who wants to acquire Shares under the Australian Retail Offer will need to complete the application form that accompanies the Australian Prospectus, in accordance with the process set out in the Australian Prospectus and any other instructions from their broker. Anthropic has applied to list its Class A common stock on the Nasdaq Global Select Market under the symbol “ANT”. Anthropic will not be applying for listing on the Australian Securities Exchange.

Us securities law disclaimer

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (“SEC”) but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This communication does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to its acceptance after the effective date. The prospectus in the registration statement and other documents Anthropic has filed with the SEC include additional information about Anthropic and the offering. Investors may get these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov. The registration statement (including the US prospectus) is available at www.sec.gov

Copyright © 2026 Stake. All rights reserved.